FDA ADVISORY COMMITTEE SPLITS ON FAMOTIDINE EFFICACY IN PREVENTING HEARTBURN
This article was originally published in The Tan Sheet
FDA ADVISORY COMMITTEE SPLITS ON FAMOTIDINE EFFICACY IN PREVENTING HEARTBURN due to questions about the crossover design of several of Merck's studies. FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees split 4-4 on whether the data supporting the OTC switch indication for the prevention/reduction of heartburn was sufficient for approval.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC